Clinical Trials Logo

Lymphoproliferative Disorders clinical trials

View clinical trials related to Lymphoproliferative Disorders.

Filter by:

NCT ID: NCT00935090 Suspended - Lymphoma Clinical Trials

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Start date: September 2009
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

NCT ID: NCT00918333 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma that has come back. Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00917826 Terminated - Clinical trials for Lympho-proliferative Diseases

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Start date: September 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.

NCT ID: NCT00900120 Withdrawn - Lymphoma Clinical Trials

Collecting and Storing Blood Samples From Patients With Cancer

Start date: March 2004
Phase:
Study type: Observational

RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood samples from patients with cancer.

NCT ID: NCT00899951 Terminated - Pain Clinical Trials

Studying Fentanyl in Patients With Cancer

Start date: October 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at fentanyl in patients with cancer.

NCT ID: NCT00890747 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Start date: August 2009
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of sunitinib malate in treating human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral therapy. Sunitinib malate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00869323 Terminated - Clinical trials for Lymphoproliferative Disorder

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Start date: March 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab works in treating patients with post-transplant lymphoproliferative disorders.

NCT ID: NCT00867529 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Start date: February 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Monoclonal antibodies, such as rituximab, can interfere with the ability of cancer cells to grow and spread. Giving rituximab before and after a donor peripheral blood stem cell transplant may help stop cancer from coming back and may help keep the patient's immune system from rejecting the donor's stem cells.

NCT ID: NCT00823524 Completed - Lymphoma Clinical Trials

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Start date: January 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant. PURPOSE: This phase I/II trial is studying the side effects and best dose of donor natural killer cells when given after a donor stem cell transplant in treating patients with advanced cancer.

NCT ID: NCT00776425 Completed - Anemia Clinical Trials

A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

Start date: January 2007
Phase: Phase 4
Study type: Interventional

This 2 arm study will investigate Quality of Life response in anemic participants with solid and lymphoid malignancies, who are receiving concomitant chemotherapy. Participants with solid and lymphoid malignancies will receive epoetin beta at a dose of 150 international units per kilogram (IU/kg) three times weekly. Participants with lymphoid malignancies will receive epoetin beta 30000 IU once weekly.